Table 5. Summary of PK parameters for docetaxel alone and in combination with pertuzumab.

Cohort	Dose group	Cycle	t1/2 (h) mean (range)	Cmax (ng ml−1) mean (range)	AUC0-∞ (ng h ml−1) mean (range)	Vss (× 104 ml m−2) mean (range)	Cl (× 103 ml h m−2) mean (range)
1	Docetaxel 60 mg m−2 alone n=6	1	16.9 (7.31–22.7)	1642 (1250–1960)	1838 (1523–2175)	79 (42–100)	33 (28–39)
1	Docetaxel 60 mg m−2+Pertuzumab 1050 mg n=6	2	19.7 (12.5–27.1)	1695 (1320–2270)	1734 (1512–2562)	102 (64–154)	36 (23–40)
2A	Docetaxel 75 mg m−2 alone n=6	1	12.7 (9.56–19.4)	3128 (2210–4580)	3744 (2386–5783)	41 (18–70)	22 (13–31)
2A	Docetaxel 75 mg m−2+Pertuzumab 420 mg n=6	2	15.2 (9.62–23.8)	2722 (1480–3830)	3496 (2178–5113)	57 (20–110)	24 (15–34)
3A	Docetaxel 100 mg m−2 alone n=5	1	9.59 (7.49–13.5)	5450 (3160–7740)	5930 (3522–8364)	25 (16–32)	18 (12–28)
3A	Docetaxel 100 mg m−2+Pertuzumab 420 mg n=4	2	12.8 (8.04–21.4)	4705 (2210–6570)	5218 (2409–7823)	43 (16–76)	22 (12–41)